Sugi Predict

Sugi Predict / Compounds / SCHEMBL5406511

SCHEMBL5406511

SCHEMBL5406511

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N4CCc5ccccc54)cc32)c(C)c1C(=O)N1CCNCC1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 5/20 0.88
▸ KDR P35968 6/20 0.55
▸ FGFR1 P11362 6/20 0.55
▸ AURKB Q96GD4 5/20 0.55
▸ AURKA O14965 4/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ CDK2 P24941 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ PTK2B Q14289 2/20 0.55
▸ TDP1 Q9NUW8 2/20 0.55
▸ CCNE1 P24864 1/20 0.55
▸ RECQL P46063 1/20 0.55
▸ FLT1 P17948 1/20 0.52
▸ PDGFRB P09619 5/20 0.46
▸ EGFR P00533 2/20 0.46
▸ ALK Q9UM73 3/20 0.46
▸ ABL1 P00519 2/20 0.46
▸ RET P07949 2/20 0.46
▸ FLT3 P36888 2/20 0.46
▸ PLK4 O00444 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29395174 0.93 MET (1.00) METKDRFGFR1AURKBAURKA
SCHEMBL29392746 0.93 MET (1.00) METKDRFGFR1AURKBAURKA
SCHEMBL2047698 0.93 MET (1.00) METKDRFGFR1AURKBAURKA
SCHEMBL2047697 0.93 MET (1.00) METKDRFGFR1AURKBAURKA
SCHEMBL5399116 0.91 MET (0.72) METKDRFGFR1AURKBAURKA
SCHEMBL5409933 0.91 MET (0.72) METKDRFGFR1AURKBAURKA
SCHEMBL5405465 0.89 MET (0.82) METKDRFGFR1AURKBAURKA
SCHEMBL5406536 0.89 MET (0.92) METKDRFGFR1AURKBAURKA
SCHEMBL5413896 0.85 MET (0.75) METKDRFGFR1AURKBAURKA
SCHEMBL5414499 0.84 MET (0.83) METKDRFGFR1AURKBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 — — US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 — — US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 — — US disclosed
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) SUGEN, INC. 2004-12-30 — — US disclosed
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. 2004-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors DMPK, MAP3K20, PHKG1 MET 2590/4885KDR 1657/4885FGFR1 1118/4885
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) CHEK2, CHEK1, ATM MET 2434/4885KDR 1541/4885FGFR1 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.